Boston Drug Patent Portfolio

Boston owns 1 orange book drug protected by 16 US patents Given below is the list of Boston's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9480652 Aerosol valve 12 May, 2032
Active
US7814943 Apparatus and method for dispensing foam 19 Nov, 2027
Active
US7731986 Therapeutic foam 17 Nov, 2024 Expired
US8122917 Apparatus and method for dispensing foam 09 Sep, 2024 Expired
US6846412 Combination filter assembly 19 Jul, 2022 Expired
US6572873 Generation of therapeutic microfoam 26 May, 2020 Expired
US6942165 Generation of therapeutic microfoam 26 May, 2020 Expired
US7025290 Generation of therapeutic microfoam 26 May, 2020 Expired
US7357336 Generation of therapeutic microfoam 26 May, 2020 Expired
US7604185 Generation of therapeutic microfoam 26 May, 2020 Expired
US7842282 Generation of therapeutic microfoam 26 May, 2020 Expired
US7842283 Generation of therapeutic microfoam 26 May, 2020 Expired
US8323677 Therapeutic foam 26 May, 2020 Expired
US8734833 Therapeutic foam 26 May, 2020 Expired
USRE40640 Injectable microfoam containing a sclerosing agent 14 Oct, 2016 Expired
USRE38919 Injectable microfoam containing a sclerosing agent 14 Oct, 2014 Expired


Given below is the list of recent legal activities going on the following drug patents of Boston.

Activity Date Patent Number
Patent litigations
Expire Patent 09 Dec, 2024 US9480652
Patent Term Extension (156) Dismissed 24 Oct, 2024 US7731986
Resp. to req. for info. sent under 37 CFR 1.750 04 Oct, 2024 US7731986
Resp. to req. for info. sent under 37 CFR 1.750 04 Sep, 2024 US7731986
Notice of Final Determination- Ineligible 20 Aug, 2024 US7731986
Requirement for information sent under 37 CFR 1.750 19 Aug, 2024 US7731986
PTE Interim Patent Extension filed 16 Aug, 2024 US7731986
Maintenance Fee Reminder Mailed 24 Jun, 2024 US9480652
Expire Patent 01 Apr, 2024 US8122917
Maintenance Fee Reminder Mailed 16 Oct, 2023 US8122917
Interim Patent Term Extension Granted 28 Feb, 2023 US7357336
Expire Patent 04 Jul, 2022 US8734833
Payment of Maintenance Fee, 12th Year, Large Entity 18 May, 2022 US7842282
Payment of Maintenance Fee, 12th Year, Large Entity 18 May, 2022 US7842283
Payment of Maintenance Fee, 12th Year, Large Entity 06 Apr, 2022 US7814943


Boston Drug Patents' Oppositions Filed in EPO

Boston drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 20, 2010, by Chemische Fabrik Kreussler & Co. Gmbh. This opposition was filed on patent number EP04798566A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP04798550A Apr, 2018 CHEMISCHE FABRIK KREUSSLER & CO. GMBH Opposition rejected
EP04798564A Sep, 2010 CHEMISCHE FABRIK KREUSSLER & CO. GMBH Patent maintained as amended
EP04798564A Sep, 2010 STRAWMAN LIMITED Patent maintained as amended
EP04798566A Apr, 2010 CHEMISCHE FABRIK KREUSSLER & CO. GMBH Patent maintained as amended


Boston's Family Patents

Boston drugs have patent protection in a total of 30 countries. It's US patent count contributes only to 16.7% of its total global patent coverage. 6 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents





Clinical Trials

Recent Clinical Trials by Boston:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) Boston Scientific Corporation NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3
A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion Cohort Boston Scientific Corporation NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3
D-cycloserine: A Novel Treatment for Gulf War Illness (GWDCS) Boston University Charles River Campus NA COMPLETED
(Aug 1, 2026)
PHASE2
MANDARIN (S6371) Boston Scientific Corporation NA COMPLETED
(Aug 1, 2026)
PHASE3
Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB Boston University NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2
Epinephrine in the Pediatric Intensive Care Unit: A Dose-Effect Trial Boston Children's Hospital NA TERMINATED
(Jul 1, 2026)
PHASE2
A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) Boston Children's Hospital NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3
Glycemic Regulation as Endometriosis Adjunct Treatment Boston Children's Hospital NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2
Valproate for the Treatment of Residual Amblyopia Boston Children's Hospital NA RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2
Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis Boston Children's Hospital NA RECRUITING
(May 1, 2026)
PHASE2
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score Boston Children's Hospital NA COMPLETED
(Apr 1, 2026)
PHASE3
Use of Indocyanine Green (ICG) for the Diagnosis of Biliary Atresia Boston Children's Hospital NA RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2
Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria Boston Children's Hospital NA ENROLLING BY INVITATION
(Mar 1, 2026)
PHASE1, PHASE2


Boston Drug List

Given below is the complete list of Boston's drugs and the patents protecting them.


1. Varithena

Varithena is protected by 16 patents, out of which 14 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9480652 Aerosol valve 12 May, 2032
(5 years from now)
Active
US7814943 Apparatus and method for dispensing foam 19 Nov, 2027
(a year from now)
Active
US7731986 Therapeutic foam 17 Nov, 2024
(2 years ago)
Expired
US8122917 Apparatus and method for dispensing foam 09 Sep, 2024
(2 years ago)
Expired
US6846412 Combination filter assembly 19 Jul, 2022
(4 years ago)
Expired
US6572873 Generation of therapeutic microfoam 26 May, 2020
(6 years ago)
Expired
US6942165 Generation of therapeutic microfoam 26 May, 2020
(6 years ago)
Expired
US7025290 Generation of therapeutic microfoam 26 May, 2020
(6 years ago)
Expired
US7357336 Generation of therapeutic microfoam 26 May, 2020
(6 years ago)
Expired
US7604185 Generation of therapeutic microfoam 26 May, 2020
(6 years ago)
Expired
US7842282 Generation of therapeutic microfoam 26 May, 2020
(6 years ago)
Expired
US7842283 Generation of therapeutic microfoam 26 May, 2020
(6 years ago)
Expired
US8323677 Therapeutic foam 26 May, 2020
(6 years ago)
Expired
US8734833 Therapeutic foam 26 May, 2020
(6 years ago)
Expired
USRE40640 Injectable microfoam containing a sclerosing agent 14 Oct, 2016
(10 years ago)
Expired
USRE38919 Injectable microfoam containing a sclerosing agent 14 Oct, 2014
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Varithena's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List